Key result
Multimodality imaging with echo and CMR differentiates HCM from physiological LVH in athletes.
Why the study?
Diagnosing HCM is challenging in young athletes due to overlapping clinical phenotypes between pathological LVH and exercise-induced physiological LVH.
This review summarizes the diagnostic challenges, sudden cardiac death risk assessment, and exercise recommendations for young athletes with hypertrophic cardiomyopathy.
Informs athlete screening and SCD risk assessment; leaves open prospective validation of protocols.
Sudden cardiac death (SCD) in a young asymptomatic individual is a devastating, unpredictable event, with a widespread impact on the public health system. Hypertrophic cardiomyopathy (HCM) is the most common form of genetic heart disease, and considered one of the leading causes of SCD affecting young and frequently asymptomatic patients. A diagnosis of HCM is challenging particularly in young athletes due to overlapping clinical phenotypesbetween pathological left ventricular hypertrophy (LVH) and exercise-induced physiological LVH. Severalinvestigational tools have been used to differentiate these two distinct entities. This review article focuses upon the diagnosis of HCM in young athletes, SCD risk assessment, and current recommendations for exercise in athletic individuals with HCM.
No takes yet. Share an insight, caveat, or question.
Srisukajorn et al. (2023) conducted a review in Hypertrophic Cardiomyopathy. Multimodality imaging, including echocardiography and cardiac magnetic resonance, is crucial for differentiating hypertrophic cardiomyopathy from physiological left ventricular hypertrophy in athletes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: